贝伐单抗治疗遗传性出血性毛细血管扩张症难治性胃肠道出血
Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab.
作者信息
Masood Muaaz, Coles Michael, Sifuentes Humberto
机构信息
Department of Internal Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Department of Gastroenterology and Hepatology, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
出版信息
Case Rep Gastrointest Med. 2021 Jun 29;2021:2242178. doi: 10.1155/2021/2242178. eCollection 2021.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis.
遗传性出血性毛细血管扩张症（HHT）是一种常染色体显性疾病，可导致包括肺、脑和胃肠道系统在内的多个器官出现血管畸形。其中一个后遗症是反复发生的胃肠道出血。贝伐单抗（Bev）正在成为治疗HHT反复胃肠道出血的一种有效疗法。Bev是一种重组单克隆抗体，可抑制血管内皮生长因子（VEGF），而VEGF是血管生成的一个重要组成部分。
Zotero 插件